Literature DB >> 12067219

Is glucagonoma of the pancreas a curable disease?

Q D Chu1, M F Al-kasspooles, J L Smith, H R Nava, H O Douglass, D Driscoll, J F Gibbs.   

Abstract

BACKGROUND: Glucagonomas are rare neuroendocrine tumors of the pancreas. Because of its rarity, its natural history is not well understood. AIM: We evaluated the natural history of glucagonomas treated at a tertiary care cancer center.
METHODS: A retrospective analysis of 12 patients during 1970 to 2000 was performed. Six patients (50%) had a tumor located in the head of the pancreas.
RESULTS: Abdominal pain (83%) and weight loss (75%) were the most common symptoms. Median tumor size was 6 cm (range 0.04-10). Seven patients (58%) had liver metastases. Five patients (42%) underwent curative resection. Overall median survival was 66 mo, and 5-yr overall survival was 66%. Five-yr overall survival was 83% for patients who had resection versus 50% for the non-resected patients (p = 0.04). Patients who were disease-free had a complete resection of the primary tumor and no liver involvement.
CONCLUSIONS: Glucagonomas generally present with liver metastases at the time of diagnosis. Cure is only possible if the disease is localized and completely resected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12067219     DOI: 10.1385/IJGC:29:3:155

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  29 in total

1.  Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon.

Authors:  D V Jones; N A Samaan; R V Sellin; J A Ajani
Journal:  Am J Med       Date:  1992-09       Impact factor: 4.965

2.  Successful treatment of metastatic glucagonoma with dacarbazine.

Authors:  T Kurose; Y Seino; H Ishida; J Fujita; T Taminato; M Matsukura; H Imura
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

3.  Metastatic islet cell tumour with clinical manifestations of insulin and glucagon excess: successful treatment by hepatic artery embolization and chemotherapy.

Authors:  S M Lee; A Forbes; R Williams
Journal:  Eur J Surg Oncol       Date:  1988-06       Impact factor: 4.424

4.  Cutaneous and oral changes as the only manifestations of the glucagonoma syndrome.

Authors:  J F Ditty; P G Lang
Journal:  South Med J       Date:  1982-02       Impact factor: 0.954

5.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

6.  Glucagonoma syndrome is an underdiagnosed clinical entity.

Authors:  J A Edney; S Hofmann; J S Thompson; A Kessinger
Journal:  Am J Surg       Date:  1990-12       Impact factor: 2.565

Review 7.  Glucagonomas and insulinomas.

Authors:  G Boden
Journal:  Gastroenterol Clin North Am       Date:  1989-12       Impact factor: 3.806

Review 8.  Gastrointestinal neuroendocrine tumors.

Authors:  R Delcore; S R Friesen
Journal:  J Am Coll Surg       Date:  1994-02       Impact factor: 6.113

9.  Hepatic transplantation for primary and metastatic cancers of the liver.

Authors:  I Penn
Journal:  Surgery       Date:  1991-10       Impact factor: 3.982

10.  Neuroendocrine gut neoplasms. Important lessons from uncommon tumors.

Authors:  H T Debas; S J Mulvihill
Journal:  Arch Surg       Date:  1994-09
View more
  3 in total

1.  Non-secreting benign glucagonoma diagnosed incidentally in a patient with refractory thrombocytopenic thrombotic purpura: report of a case.

Authors:  Georgios K Georgiou; Ioannis Gizas; Konstantinos P Katopodis; Christos S Katsios
Journal:  Surg Today       Date:  2014-11-06       Impact factor: 2.549

Review 2.  Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know.

Authors:  Charles de Ponthaud; Fabrice Menegaux; Sébastien Gaujoux
Journal:  Cancers (Basel)       Date:  2021-11-27       Impact factor: 6.639

3.  Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.

Authors:  Giuseppe Corrias; Natally Horvat; Serena Monti; Olca Basturk; Oscar Lin; Luca Saba; Lisa Bodei; Diane L Reidy; Lorenzo Mannelli
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.